Comprehensive Genomic Profiling (CGP) assays are increasingly utilized in clinical practices, offering an efficient means of maximizing the utility of limited tissue biopsies by assessing multiple cancer-relevant biomarkers simultaneously. By covering actionable and potentially actionable biomarkers, CGP assays hold promise in identifying diverse therapeutic pathways and innovative clinical trial options for cancer patients.
The AmoyDx® Master Panel represents a leading CGP assay that encompasses a wide array of genomic signatures, including HRD, MSI, and TMB, thereby advancing biomarker identification and cancer treatment research across various tumor types.
The Master Panel facilitates the concurrent detection of both DNA and RNA biomarkers. On the DNA level, it encompasses 571 genes, encompassing biomarkers associated with approved targeted therapies, as well as those recommended by guidelines/consensus or under investigation in clinical trials. In addition to SNV/indel, fusion, and CNV analysis, the Master Panel also evaluates complex signatures such as HRD, MSI, and TMB. On the RNA level, it surveys over 2000 genes, detecting fusions and alternative splicing while analyzing levels of genes implicated in cancer pathways. Furthermore, it enables the assessment of select immunotherapy biomarkers like GEP and TME.
The AmoyDx® Master Panel represents a leading CGP assay that encompasses a wide array of genomic signatures, including HRD, MSI, and TMB, thereby advancing biomarker identification and cancer treatment research across various tumor types.
The Master Panel facilitates the concurrent detection of both DNA and RNA biomarkers. On the DNA level, it encompasses 571 genes, encompassing biomarkers associated with approved targeted therapies, as well as those recommended by guidelines/consensus or under investigation in clinical trials. In addition to SNV/indel, fusion, and CNV analysis, the Master Panel also evaluates complex signatures such as HRD, MSI, and TMB. On the RNA level, it surveys over 2000 genes, detecting fusions and alternative splicing while analyzing levels of genes implicated in cancer pathways. Furthermore, it enables the assessment of select immunotherapy biomarkers like GEP and TME.
Specifications
Target regions
DNA: 571 genes; RNA: 2660 genes
Alterations detected
DNA: SNVs/Indels, Fusions, CNV, TMB, MSI, HRD;
RNA: Fusions, GeneExp, GEP, TME, EBV
RNA: Fusions, GeneExp, GEP, TME, EBV
Data output per sample
DNA: 10Gb; RNA: 2Gb
Sequencer
Illumina NovaSeq 6000; NextSeq 500/550
Publications
1. Kunimasa, K., Matsumoto, S., Honma, K. et al. Utility of needle biopsy in centrally located lung cancer for genome analysis: a retrospective cohort study. BMC Pulm Med 23, 484 (2023).
2. Atsushi OHTSU, Koichi GOTO, Takayuki YOSHINO. Improvement of patient care using cancer genomic profiling: SCRUM-/CIRCULATE-Japan experience. Proceedings of the Japan Academy, Series B, 2023, Volume 99, Issue 8, Pages 241-253.
3. Li S, Hou L, Huang Y, et alPrimary salivary duct carcinoma of the lung: clinicopathological features, diagnosis and practical challengesJournal of Clinical Pathology Published Online First: 25 January 2023.
Inquiry